Tristel PLC (TSTL.L)
ValueMarkers Composite Index
72% below intrinsic value ($19)
Tristel PLC (TSTL.L) — VMCI valuation read
The headline on Tristel PLC (TSTL.L) is a 59/100 VMCI score, set against a Healthcare sector median of 50. That 9-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.
TSTL.L insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.
**Investor frame.** TSTL.L trades at 21.0x earnings, 17% above the Healthcare median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 0.7x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on TSTL.L.
TSTL.L fell 2.9% over the trailing 7 days, with a -13.1% read on a 30-day basis.
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.